HUP0003397A3 - Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione for producing medicament useful in the treatment of polycystic ovary syndrome and gestational diabetes - Google Patents

Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione for producing medicament useful in the treatment of polycystic ovary syndrome and gestational diabetes

Info

Publication number
HUP0003397A3
HUP0003397A3 HU0003397A HUP0003397A HUP0003397A3 HU P0003397 A3 HUP0003397 A3 HU P0003397A3 HU 0003397 A HU0003397 A HU 0003397A HU P0003397 A HUP0003397 A HU P0003397A HU P0003397 A3 HUP0003397 A3 HU P0003397A3
Authority
HU
Hungary
Prior art keywords
thiazolidinedione
pyridyl
ethoxy
benzyl
amino
Prior art date
Application number
HU0003397A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HUP0003397A2 publication Critical patent/HUP0003397A2/hu
Publication of HUP0003397A3 publication Critical patent/HUP0003397A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0003397A 1997-05-15 1998-05-14 Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione for producing medicament useful in the treatment of polycystic ovary syndrome and gestational diabetes HUP0003397A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/856,987 US5874454A (en) 1993-09-15 1997-05-15 Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
PCT/US1998/010113 WO1998051305A1 (en) 1997-05-15 1998-05-14 Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes

Publications (2)

Publication Number Publication Date
HUP0003397A2 HUP0003397A2 (hu) 2002-01-28
HUP0003397A3 true HUP0003397A3 (en) 2002-02-28

Family

ID=25324901

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003397A HUP0003397A3 (en) 1997-05-15 1998-05-14 Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione for producing medicament useful in the treatment of polycystic ovary syndrome and gestational diabetes

Country Status (14)

Country Link
US (1) US5874454A (hu)
EP (1) EP0981346A1 (hu)
JP (1) JP2001525827A (hu)
KR (1) KR20010012556A (hu)
AU (1) AU731690B2 (hu)
BR (1) BR9809120A (hu)
CA (1) CA2282473A1 (hu)
HU (1) HUP0003397A3 (hu)
IL (1) IL132125A0 (hu)
IS (1) IS5177A (hu)
NO (1) NO995549D0 (hu)
PL (1) PL336764A1 (hu)
WO (1) WO1998051305A1 (hu)
ZA (1) ZA984084B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
BRPI0809583B1 (pt) 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
CN114805533A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
RU2665969C1 (ru) * 2017-05-04 2018-09-05 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ лечения синдрома поликистозных яичников

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
CA2071629C (en) * 1990-02-09 1997-12-30 Jerry R. Colca Use of insulin sensitizing agents to treat hypertension
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
CA2111096C (en) * 1991-06-25 1997-01-14 Steven Wayne Goldstein Thiazolidinedione hypoglycemic agents
WO1995007694A1 (en) * 1993-09-15 1995-03-23 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus

Also Published As

Publication number Publication date
IS5177A (is) 1999-09-10
CA2282473A1 (en) 1998-11-19
BR9809120A (pt) 2000-08-01
ZA984084B (en) 1998-11-20
NO995549L (no) 1999-11-12
AU731690B2 (en) 2001-04-05
JP2001525827A (ja) 2001-12-11
KR20010012556A (ko) 2001-02-15
HUP0003397A2 (hu) 2002-01-28
PL336764A1 (en) 2000-07-17
WO1998051305A1 (en) 1998-11-19
US5874454A (en) 1999-02-23
AU7494998A (en) 1998-12-08
IL132125A0 (en) 2001-03-19
NO995549D0 (no) 1999-11-12
EP0981346A1 (en) 2000-03-01

Similar Documents

Publication Publication Date Title
HUP0003876A3 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
MY129897A (en) Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
HUP0003397A3 (en) Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione for producing medicament useful in the treatment of polycystic ovary syndrome and gestational diabetes
NO2009002I1 (no) 5-{4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl}tiazolidin-2,4-dionmaleat(salter/solvater)+glimepirid
HUP0100509A3 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical, process for its preparation and its pharmaceutical use
MA26511A1 (fr) Compositions pharmaceutiques comprenant de la 5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy) benzyl)-thiazolidine-2,4-dione et de l'insuline pour une methode de traitement.
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
MY129475A (en) Process for the preparation of substituted thiazolidinedione
WO2000063205A3 (en) Thiazolidinedione derivative and its use as antidiabetic
AU2002343036A1 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl)thiazolidine-2,4-dione and pharmaceutical compositions comprising the same
PT1349855E (pt) Sal misilato de 5-{4-[2-(n-metil-n-(2-piridil)amino)etoxi]benzil}tiazolidino-2, 4-diona
AP1814A (en) Tartrate salts of thiazolidinedione derivative.
SI1315723T1 (en) The hydrochloride salt of 5(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione
WO2000063206A3 (en) Thiazolidinedione derivative and its use as antidiabetic
GB0021784D0 (en) Novel pharmaceutical
MXPA02012100A (es) Sal de tiazodilindiona para el tratamiento de la diabetes mellitus.
PT1446404E (pt) Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos
HUP0301799A3 (en) Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide for treating diabetes mellitus, process for preparation thereof and pharmaceutical composition containing the same
AP1785A (en) Tartrate salt of thiazolidinedione derivative.
AU2002352479A1 (en) 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.
HU9802875D0 (en) Process for producing 2-(methylthio)-5-(trifluoromethyl)-1,3,4-thiadiazole using methyldithio carbazinate and trifluoroacetic acid
AU2002350563A1 (en) Pharmaceutical composition comprising a glitazone and a thiazolidinedione derivative, and use thereof for treating diabetes
AU2382701A (en) Thiazolidinedione derivatives in treatment of diabetes mellitus of type
IL166189A (en) 5-{4-[2-(n-methyl-n-(2-pyridyl) amino) ethoxy] benzyl}-5-{1-[2, 4-dioxothiazolidine-5-yl]-1-[4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy) phenyl] methyl}-2,4-thiazolidinedione and tautomeric form, salt or solvate thereof